Bending the cost curve in AAV manufacturing via scalable platform innovation, productivity gains, and analytical insight

AAV manufacturing platforms represent a leap into next-generation technologies that are set to drive gene therapy commercialization. Selecting the right approach for AAV production is key to meeting productivity and scalability goals. Through case studies and data, we explore strategies to develop simplified, scalable state-of-the-art platforms to fulfill the demands for commercial gene therapy manufacturing. Here, we will provide an overview of our AAV production platforms, including the novel AAV stable producer cell line (PCL) platform designed to optimize AAV yields and process efficiency. Additionally, evaluation and implementation of innovative approaches to address the current lack of robust analytics, achieve comprehensive characterization of the AAV product, and improve AAV processes will be discussed. These technologies will be made available to the wider scientific community under a research license, or via Lonza’s CDMO service offerings.

AAV gene therapy manufacturing faces critical bottlenecks in productivity, process consistency, and characterization. This article examines platform innovations in transient transfection, stable producer cell lines, and 3D digital PCR analytics that address these challenges at commercial scale.

What you will learn

01

How the Xcite^® transient transfection platform achieves 2–20× titer improvements and >30% full capsid ratios across multiple AAV serotypes

02

Why stable producer cell lines eliminate GMP plasmid requirements, reduce batch variability, and enable titers exceeding 1×10¹² vg/mL

03

How 3D ddPCR linkage analysis provides genome integrity assessment beyond titer, differentiating true linkage from false-positive results

The AAV manufacturing platform

1

Transient transfection

2

Stable PCL development

3

Bioreactor scale-up

4

3D ddPCR characterization

Key findings

2–20-fold titer improvements over control systems demonstrated across AAV2, 5, 6, 8, 9, and Anc80 serotypes using the Xcite^® three-plasmid system with the 28D5 cell line

Stable PCL top performers produce 10–15× higher titers than transient transfection processes, with stable productivity maintained through at least 30 passages

3D ddPCR linkage analysis validated against nanopore sequencing provides a reliable surrogate for functional assays during early-stage process development and vector design optimization

Key interests

Gene Therapy

AAV Manufacturing

Producer Cell Lines

Digital PCR

Analytical Development & QC

Process Scalability